Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents
Publisher's version (útgefin grein) A nationwide programme for the treatment of all patients infected with hepatitis C virus (HCV) was launched in Iceland in January 2016. By providing universal access to direct‐acting antiviral agents to the entire patient population, the two key aims of the p...
Published in: | Journal of Internal Medicine |
---|---|
Main Authors: | , , , , , , , , , , , , , , |
Other Authors: | , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Wiley
2018
|
Subjects: | |
Online Access: | https://hdl.handle.net/20.500.11815/1060 https://doi.org/10.1111/joim.12740 |
id |
ftopinvisindi:oai:opinvisindi.is:20.500.11815/1060 |
---|---|
record_format |
openpolar |
spelling |
ftopinvisindi:oai:opinvisindi.is:20.500.11815/1060 2023-05-15T16:47:29+02:00 Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents Ólafsson, Sigurður Tyrfingsson, Þórarinn Rúnarsdóttir, Valgerður Bergmann, Óttar Már Hansdóttir, Ingunn Björnsson, Einar Stefán Jóhannsson, B. Sigurðardóttir, Bryndís Fridriksdóttir, R. H. Löve, Arthur Hellard, M. Löve, Þorvarður Jón Gudnason, Thorarinn Heimisdottir, María Gottfredsson, Magnus Læknadeild (HÍ) Faculty of Medicine (UI) Sálfræðideild (HÍ) Faculty of Psychology (UI) Heilbrigðisvísindasvið (HÍ) School of Health Sciences (UI) Háskóli Íslands University of Iceland 2018-03-07 500-507 https://hdl.handle.net/20.500.11815/1060 https://doi.org/10.1111/joim.12740 en eng Wiley Journal of Internal Medicine;283(5) Olafsson, S., Tyrfingsson, T., Runarsdottir, V., Bergmann, O. M., Hansdottir, I., Björnsson, E. S., . . . Gottfredsson, M. (2018). Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct-acting antiviral agents. Journal of Internal Medicine, 283(5), 500-507. doi:10.1111/joim.1274 0954-6820 1365-2796 (eISSN) https://hdl.handle.net/20.500.11815/1060 Journal of Internal Medicine doi:10.1111/joim.12740 info:eu-repo/semantics/openAccess Direct‐acting antiviral agents Elimination Hepatitis C Intravenous drug use Policy Prevention Veirusjúkdómar Lifrarbólga C Lyf Forvarnir info:eu-repo/semantics/article 2018 ftopinvisindi https://doi.org/20.500.11815/1060 https://doi.org/10.1111/joim.12740 https://doi.org/10.1111/joim.1274 2022-11-18T06:51:43Z Publisher's version (útgefin grein) A nationwide programme for the treatment of all patients infected with hepatitis C virus (HCV) was launched in Iceland in January 2016. By providing universal access to direct‐acting antiviral agents to the entire patient population, the two key aims of the project were to (i) offer a cure to patients and thus reduce the long‐term sequelae of chronic hepatitis C, and (ii) to reduce domestic incidence of HCV in the population by 80% prior to the WHO goal of HCV elimination by the year 2030. An important part of the programme is that vast majority of cases will be treated within 36 months from the launch of the project, during 2016–2018. Emphasis is placed on early case finding and treatment of patients at high risk for transmitting HCV, that is people who inject drugs (PWID), as well as patients with advanced liver disease. In addition to treatment scale‐up, the project also entails intensification of harm reduction efforts, improved access to diagnostic tests, as well as educational campaigns to curtail spread, facilitate early detection and improve linkage to care. With these efforts, Iceland is anticipated to achieve the WHO hepatitis C elimination goals well before 2030. This article describes the background and organization of this project. Clinical trial number: NCT02647879. Sigurdur Olafsson: Speaker's fee from Merck. Magnus Gottfredsson: Speaker's fee from Astellas and Gilead. MH and the Burnet Institute receive investigator‐initiated research funding from Gilead Sciences, AbbVie and BMS. Peer Reviewed Article in Journal/Newspaper Iceland Opin vísindi (Iceland) Journal of Internal Medicine 283 5 500 507 |
institution |
Open Polar |
collection |
Opin vísindi (Iceland) |
op_collection_id |
ftopinvisindi |
language |
English |
topic |
Direct‐acting antiviral agents Elimination Hepatitis C Intravenous drug use Policy Prevention Veirusjúkdómar Lifrarbólga C Lyf Forvarnir |
spellingShingle |
Direct‐acting antiviral agents Elimination Hepatitis C Intravenous drug use Policy Prevention Veirusjúkdómar Lifrarbólga C Lyf Forvarnir Ólafsson, Sigurður Tyrfingsson, Þórarinn Rúnarsdóttir, Valgerður Bergmann, Óttar Már Hansdóttir, Ingunn Björnsson, Einar Stefán Jóhannsson, B. Sigurðardóttir, Bryndís Fridriksdóttir, R. H. Löve, Arthur Hellard, M. Löve, Þorvarður Jón Gudnason, Thorarinn Heimisdottir, María Gottfredsson, Magnus Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
topic_facet |
Direct‐acting antiviral agents Elimination Hepatitis C Intravenous drug use Policy Prevention Veirusjúkdómar Lifrarbólga C Lyf Forvarnir |
description |
Publisher's version (útgefin grein) A nationwide programme for the treatment of all patients infected with hepatitis C virus (HCV) was launched in Iceland in January 2016. By providing universal access to direct‐acting antiviral agents to the entire patient population, the two key aims of the project were to (i) offer a cure to patients and thus reduce the long‐term sequelae of chronic hepatitis C, and (ii) to reduce domestic incidence of HCV in the population by 80% prior to the WHO goal of HCV elimination by the year 2030. An important part of the programme is that vast majority of cases will be treated within 36 months from the launch of the project, during 2016–2018. Emphasis is placed on early case finding and treatment of patients at high risk for transmitting HCV, that is people who inject drugs (PWID), as well as patients with advanced liver disease. In addition to treatment scale‐up, the project also entails intensification of harm reduction efforts, improved access to diagnostic tests, as well as educational campaigns to curtail spread, facilitate early detection and improve linkage to care. With these efforts, Iceland is anticipated to achieve the WHO hepatitis C elimination goals well before 2030. This article describes the background and organization of this project. Clinical trial number: NCT02647879. Sigurdur Olafsson: Speaker's fee from Merck. Magnus Gottfredsson: Speaker's fee from Astellas and Gilead. MH and the Burnet Institute receive investigator‐initiated research funding from Gilead Sciences, AbbVie and BMS. Peer Reviewed |
author2 |
Læknadeild (HÍ) Faculty of Medicine (UI) Sálfræðideild (HÍ) Faculty of Psychology (UI) Heilbrigðisvísindasvið (HÍ) School of Health Sciences (UI) Háskóli Íslands University of Iceland |
format |
Article in Journal/Newspaper |
author |
Ólafsson, Sigurður Tyrfingsson, Þórarinn Rúnarsdóttir, Valgerður Bergmann, Óttar Már Hansdóttir, Ingunn Björnsson, Einar Stefán Jóhannsson, B. Sigurðardóttir, Bryndís Fridriksdóttir, R. H. Löve, Arthur Hellard, M. Löve, Þorvarður Jón Gudnason, Thorarinn Heimisdottir, María Gottfredsson, Magnus |
author_facet |
Ólafsson, Sigurður Tyrfingsson, Þórarinn Rúnarsdóttir, Valgerður Bergmann, Óttar Már Hansdóttir, Ingunn Björnsson, Einar Stefán Jóhannsson, B. Sigurðardóttir, Bryndís Fridriksdóttir, R. H. Löve, Arthur Hellard, M. Löve, Þorvarður Jón Gudnason, Thorarinn Heimisdottir, María Gottfredsson, Magnus |
author_sort |
Ólafsson, Sigurður |
title |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_short |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_full |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_fullStr |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_full_unstemmed |
Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents |
title_sort |
treatment as prevention for hepatitis c (trap hep c) - a nationwide elimination programme in iceland using direct-acting antiviral agents |
publisher |
Wiley |
publishDate |
2018 |
url |
https://hdl.handle.net/20.500.11815/1060 https://doi.org/10.1111/joim.12740 |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
Journal of Internal Medicine;283(5) Olafsson, S., Tyrfingsson, T., Runarsdottir, V., Bergmann, O. M., Hansdottir, I., Björnsson, E. S., . . . Gottfredsson, M. (2018). Treatment as Prevention for Hepatitis C (TraP Hep C) – a nationwide elimination programme in Iceland using direct-acting antiviral agents. Journal of Internal Medicine, 283(5), 500-507. doi:10.1111/joim.1274 0954-6820 1365-2796 (eISSN) https://hdl.handle.net/20.500.11815/1060 Journal of Internal Medicine doi:10.1111/joim.12740 |
op_rights |
info:eu-repo/semantics/openAccess |
op_doi |
https://doi.org/20.500.11815/1060 https://doi.org/10.1111/joim.12740 https://doi.org/10.1111/joim.1274 |
container_title |
Journal of Internal Medicine |
container_volume |
283 |
container_issue |
5 |
container_start_page |
500 |
op_container_end_page |
507 |
_version_ |
1766037569133346816 |